Pfizer Halts Obesity Pill Tests Amid Safety Concerns
Pfizer's pursuit of a daily pill to tackle obesity has hit a setback. The pharmaceuticals giant has paused development of its oral obesity drug, danuglipron, after a possible liver injury experienced by a trial participant. The incident occurred during...
Newser